• 1. University of Science and Technology of China, Hefei 230026, China;
  • 2. Suzhou Institute for Advanced Research, University of Science and Technology of China, Suzhou 215123, China;
  • 3. Department of Ophthalmology, Zhejiang Provincial People's Hospital, Hangzhou 310000, China;
  • 4. Hefei Orbis Biotech LTD, Hefei 230000, China;
  • 5. Eye Hospital of Wenzhou Medical University, Wenzhou 325000, China;
Sun Mingzhai, Email: mingzhai@ustc.edu.cn
Export PDF Favorites Scan Get Citation

Retinopathy of prematurity (ROP) is a major cause of vision loss and blindness among premature infants. Timely screening, diagnosis, and intervention can effectively prevent the deterioration of ROP. However, there are several challenges in ROP diagnosis globally, including high subjectivity, low screening efficiency, regional disparities in screening coverage, and severe shortage of pediatric ophthalmologists. The application of artificial intelligence (AI) as an assistive tool for diagnosis or an automated method for ROP diagnosis can improve the efficiency and objectivity of ROP diagnosis, expand screening coverage, and enable automated screening and quantified diagnostic results. In the global environment that emphasizes the development and application of medical imaging AI, developing more accurate diagnostic networks, exploring more effective AI-assisted diagnosis methods, and enhancing the interpretability of AI-assisted diagnosis, can accelerate the improvement of AI policies of ROP and the implementation of AI products, promoting the development of ROP diagnosis and treatment.

Citation: Wu Di, Mao Jianbo, Lu Yu, Xu Xiaorong, Shen Lijun, Sun Mingzhai. Research progress on the application of artificial intelligence in the screening and treatment of retinopathy of prematurity. Chinese Journal of Ocular Fundus Diseases, 2023, 39(12): 1022-1027. doi: 10.3760/cma.j.cn511434-20230109-00013 Copy

  • Previous Article

    Research progress of choroidal vascular index in diabetic retinopathy
  • Next Article

    Recent advances in suprachoroidal drug delivery for the treatment of ocular posterior segment diseases